The incidence of
non-small-cell lung cancer (NSCLC) in Russia is the highest among the BRIC
(Brazil, Russia, India, China) markets, and is comparable to that of the United
Kingdom and the United States. Increasing risk of non-small-cell lung cancer
due to increasing smoking prevalence, in conjunction with an aging population,
will drive an increase in incident non-small-cell lung cancer cases in Russia
through 2020. In this report, we examine the trends within Russia’s NSCLC
therapy market, which is characterized by the growing incident
population, gradually increasing use of higher-priced
chemotherapies and the introduction of several premium-priced
Primary research: 90 oncologists surveyed across Russia (including 60 oncologists surveyed in four major cities [Moscow, Saint Petersburg, Novosibirsk, and Ekaterinburg]). Separate in-depth interviews with 8 Russian oncologists.
Epidemiology: Total incident cases of NSCLC in Russia over a ten-year period (2010-2020) by age, by gender, by histology, by Federal District, and by major city.
Current therapies and medical practice: Reporting use of brands and generics for the NSCLC treatments available in Russia.
Pricing and reimbursement: Prices of NSCLC therapies in Russia versus other major markets and analysis of the impact of government reimbursement on treatment trends.
Market forecast features: Our analysis evaluates rates of NSCLC progression and rates of drug treatment with NSCLC therapies, across all stages of the disease. We include a detailed forecast of current and emerging therapies within platinum agents, taxanes, antimetabolites, vinca alkaloids, topoisomerase II inhibitors, DNA-interacting agents, VEGF/EGFR monoclonal antibodies, kinase inhibitors, and PARP inhibitors classes of drugs, from 2010 through 2015, using a combination of historical trend analysis and an epidemiology-based, bottom-up market model.